Randomized Comparative Trial of High-dose FARESTON for Aromatase Inhibitor resistant breast cancer compared to Faslodex
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Toremifene (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HI-FAIR
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
- 20 Sep 2015 Planned End Date changed from 31 Mar 2017 to 31 Mar 2016, as reported by University Hospital Medical Information Network - Japan record.
- 20 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan.